Examkin

Question

Difficulty: HardRheumatology and Immunology

A middle-aged patient with stage 3 chronic kidney disease is evaluated for a maximally swollen, erythematous, and exquisitely tender first metatarsophalangeal joint. This marks the third similar episode within the past twelve months. Previous synovial fluid analysis definitively identified negatively birefringent, needle-shaped crystals. The attending physician outlines a comprehensive pharmacological protocol aimed at resolving the current symptoms and eventually depleting the total body urate pool. Arrange the following therapeutic steps in the correct chronological sequence, from immediate acute management to long-term maintenance.

  1. 1Administration of an oral glucocorticoid taper to achieve complete resolution of the acute joint inflammation.
  2. 2Initiation of a xanthine oxidase inhibitor accompanied by a low-dose prophylactic anti-inflammatory agent.
  3. 3Progressive dose escalation of the urate-lowering medication to achieve a serum uric acid level below <6.0< 6.0 mg/dL.
  4. 4Cessation of the prophylactic anti-inflammatory agent following several months of symptom-free target maintenance.

Answer

The correct chronological sequence is: 1) Administer an oral glucocorticoid taper, 2) Initiate a xanthine oxidase inhibitor with anti-inflammatory prophylaxis, 3) Titrate the medication to achieve a serum uric acid <6.0< 6.0 mg/dL, and 4) Cease the prophylactic agent after months of target maintenance.
The correct sequence reflects the standard stepwise approach to chronic gout management in patients with renal impairment. Acute inflammation is first controlled with renal-safe agents (glucocorticoids). Subsequently, urate-lowering therapy is initiated alongside prophylaxis to prevent mobilization flares. The urate-lowering therapy is then actively titrated to a specific biochemical target. Finally, once clinical stability is achieved, prophylaxis is withdrawn to minimize long-term medication burden.

Step-by-Step Solution

1
Control the acute flare with a renal-safe agent (oral glucocorticoids).
Complete resolution of acute joint inflammation and pain.
Acute flares must be resolved prior to focusing on long-term management. Glucocorticoids are preferred over NSAIDs or full-dose colchicine in patients with stage 3 chronic kidney disease.
2
Start a xanthine oxidase inhibitor (e.g., allopurinol) with concurrent low-dose prophylaxis.
Reduction of systemic urate production while preventing acute mobilization flares.
Rapid decreases in serum urate can precipitate paradoxical attacks; thus, low-dose prophylaxis (e.g., prednisone or adjusted-dose colchicine) is required when initiating urate-lowering therapy.
3
Titrate the xanthine oxidase inhibitor dose based on laboratory monitoring.
Serum urate decreases to the therapeutic target of <6.0< 6.0 mg/dL.
Fixed-dose urate-lowering therapy is often insufficient; a treat-to-target approach is necessary to gradually dissolve existing monosodium urate crystal deposits.
4
Discontinue the prophylactic agent while continuing the xanthine oxidase inhibitor.
Patient remains on lifelong urate-lowering monotherapy without unnecessary drug toxicity.
Once the target urate level is sustained for 3 to 6 months without subsequent flares, the risk of mobilization flares drops significantly, rendering prophylaxis unnecessary.

Key Concept

The sequential pharmacological management of gout requires resolving the acute flare with comorbidity-appropriate agents, initiating treat-to-target urate-lowering therapy with concurrent prophylaxis, and eventually withdrawing prophylaxis once the urate target is durably maintained.
Estimated Time:1m 30s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic